A phase II trial of the Src-kinase inhibitor saracatinib after four cycles of chemotherapy for patients with extensive stage small cell lung cancer: NCCTG trial N-0621
- 1 May 2014
- journal article
- research article
- Published by Elsevier in Lung Cancer
- Vol. 85 (2) , 245-250
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- A Phase II Study of Dasatinib in Patients with Chemosensitive Relapsed Small Cell Lung Cancer (Cancer and Leukemia Group B 30602)Journal of Thoracic Oncology, 2010
- Randomized Phase II Study of Carboplatin and Etoposide With or Without thebcl-2Antisense Oligonucleotide Oblimersen for Extensive-Stage Small-Cell Lung Cancer: CALGB 30103Journal of Clinical Oncology, 2008
- Irinotecan, Carboplatin, and Imatinib in Untreated Extensive-Stage Small-Cell Lung Cancer: A Phase II Trial of the Minnie Pearl Cancer Research NetworkJournal of Thoracic Oncology, 2007
- Src-Family Kinases Are Activated in Non-Small Cell Lung Cancer and Promote the Survival of Epidermal Growth Factor Receptor-Dependent Cell LinesThe American Journal of Pathology, 2007
- Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell cancers: A Hoosier Oncology Group phase II trialLung Cancer, 2006
- Src activation regulates anoikis in human colon tumor cell linesOncogene, 2002
- A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysisLung Cancer, 2000
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000
- CELLULAR FUNCTIONS REGULATED BY SRC FAMILY KINASESAnnual Review of Cell and Developmental Biology, 1997
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958